NEOGENOMICS INC (NEO) Stock Fundamental Analysis
NASDAQ:NEO - Nasdaq - US64049M2098 - Common Stock - Currency: USD
Taking everything into account, NEO scores 3 out of 10 in our fundamental rating. NEO was compared to 103 industry peers in the Health Care Providers & Services industry. NEO has a bad profitability rating. Also its financial health evaluation is rather negative. NEO is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
NEO had positive earnings in the past year.
In the past year NEO had a positive cash flow from operations.
NEO had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NEO reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -4.84%, NEO is not doing good in the industry: 68.93% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -8.73%, NEO is in line with its industry, outperforming 40.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.84% | ||
| ROE | -8.73% | ||
| ROIC | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 44.30%, NEO is doing good in the industry, outperforming 72.82% of the companies in the same industry.
In the last couple of years the Gross Margin of NEO has declined.
The Profit Margin and Operating Margin are not available for NEO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
2. Health
2.1 Basic Checks
NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NEO has more shares outstanding
NEO has more shares outstanding than it did 5 years ago.
NEO has a worse debt/assets ratio than last year.
2.2 Solvency
NEO has an Altman-Z score of 0.97. This is a bad value and indicates that NEO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.97, NEO is not doing good in the industry: 70.87% of the companies in the same industry are doing better.
NEO has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NEO (0.38) is better than 62.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.97 |
ROIC/WACCN/A
WACC6.62%
2.3 Liquidity
NEO has a Current Ratio of 2.05. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
NEO has a Current ratio of 2.05. This is in the better half of the industry: NEO outperforms 74.76% of its industry peers.
A Quick Ratio of 1.95 indicates that NEO should not have too much problems paying its short term obligations.
The Quick ratio of NEO (1.95) is better than 74.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.05 | ||
| Quick Ratio | 1.95 |
3. Growth
3.1 Past
NEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 400.00%, which is quite impressive.
Measured over the past years, NEO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.25% on average per year.
NEO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.10%.
Measured over the past years, NEO shows a quite strong growth in Revenue. The Revenue has been growing by 10.07% on average per year.
EPS 1Y (TTM)400%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%100%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%7.55%
3.2 Future
NEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.11% yearly.
NEO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.61% yearly.
EPS Next Y60.23%
EPS Next 2Y72.97%
EPS Next 3Y72.32%
EPS Next 5Y51.11%
Revenue Next Year12.61%
Revenue Next 2Y11.99%
Revenue Next 3Y11.44%
Revenue Next 5Y11.61%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 60.50, which means the current valuation is very expensive for NEO.
Compared to the rest of the industry, the Price/Earnings ratio of NEO is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 27.30, NEO is valued quite expensively.
Based on the Price/Forward Earnings ratio of 24.27, the valuation of NEO can be described as rather expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as NEO.
NEO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.5 | ||
| Fwd PE | 24.27 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NEO's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NEO's earnings are expected to grow with 72.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)1
PEG (5Y)N/A
EPS Next 2Y72.97%
EPS Next 3Y72.32%
5. Dividend
5.1 Amount
No dividends for NEO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.26
-0.23 (-3.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners100.43%
Inst Owner Change0%
Ins Owners1.09%
Ins Owner Change3.42%
Market Cap934.29M
Analysts76.84
Price Target11.17 (53.86%)
Short Float %3.39%
Short Ratio1.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)67.51%
Min EPS beat(2)35.03%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)326.2%
Min EPS beat(4)35.03%
Max EPS beat(4)871.51%
EPS beat(8)8
Avg EPS beat(8)217.51%
EPS beat(12)12
Avg EPS beat(12)158.96%
EPS beat(16)16
Avg EPS beat(16)126.24%
Revenue beat(2)0
Avg Revenue beat(2)-2.17%
Min Revenue beat(2)-2.68%
Max Revenue beat(2)-1.66%
Revenue beat(4)1
Avg Revenue beat(4)-1.06%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)0.63%
Revenue beat(8)5
Avg Revenue beat(8)1.5%
Revenue beat(12)9
Avg Revenue beat(12)2.54%
Revenue beat(16)10
Avg Revenue beat(16)1.69%
PT rev (1m)0.73%
PT rev (3m)-39.14%
EPS NQ rev (1m)4.61%
EPS NQ rev (3m)-48.58%
EPS NY rev (1m)-11.25%
EPS NY rev (3m)-10.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)0.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.5 | ||
| Fwd PE | 24.27 | ||
| P/S | 1.39 | ||
| P/FCF | N/A | ||
| P/OCF | 122.76 | ||
| P/B | 1.05 | ||
| P/tB | 27.33 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.12
EY1.65%
EPS(NY)0.3
Fwd EY4.12%
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)0.06
OCFY0.81%
SpS5.22
BVpS6.9
TBVpS0.27
PEG (NY)1
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.84% | ||
| ROE | -8.73% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.3% | ||
| FCFM | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
F-Score6
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 55.52% | ||
| Cap/Sales | 5.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.05 | ||
| Quick Ratio | 1.95 | ||
| Altman-Z | 0.97 |
F-Score6
WACC6.62%
ROIC/WACCN/A
Cap/Depr(3y)46.9%
Cap/Depr(5y)68.48%
Cap/Sales(3y)5.71%
Cap/Sales(5y)7.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)400%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%100%
EPS Next Y60.23%
EPS Next 2Y72.97%
EPS Next 3Y72.32%
EPS Next 5Y51.11%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%7.55%
Revenue Next Year12.61%
Revenue Next 2Y11.99%
Revenue Next 3Y11.44%
Revenue Next 5Y11.61%
EBIT growth 1Y9.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year159.59%
EBIT Next 3Y46.57%
EBIT Next 5Y31.13%
FCF growth 1Y60.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y115.33%
OCF growth 3YN/A
OCF growth 5Y-21.37%